➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Medtronic
McKinsey
Johnson and Johnson
Colorcon

Last Updated: March 3, 2021

DrugPatentWatch Database Preview

CHORIONIC GONADOTROPIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for CHORIONIC GONADOTROPIN

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Baylor College of MedicineEarly Phase 1
Merck, S.L., SpainPhase 4
Fundación Santiago Dexeus FontPhase 4

See all CHORIONIC GONADOTROPIN clinical trials

Recent Litigation for CHORIONIC GONADOTROPIN

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ravgen, Inc. v. Progenity, Inc.2020-12-20
Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals of New York, LLC2018-12-19
Amgen Inc. v. Accord Healthcare, Inc.2018-06-28

See all CHORIONIC GONADOTROPIN litigation

PTAB Litigation
PetitionerDate
Quest Diagnostics Incorporated2020-09-11
2017-01-10
2013-07-29

See all CHORIONIC GONADOTROPIN litigation

Patent Text Search: US Patents for CHORIONIC GONADOTROPIN

These patents were identified by searching patent claims

Supplementary Protection Certificates for CHORIONIC GONADOTROPIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
6/2010 Austria   Start Trial PRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTRATION NO/DATE: EU/1/09/609/001-002 20100125
CA 2017 00022 Denmark   Start Trial PRODUCT NAME: REKOMBINANT FSH (RFSH) INKLUDERENDE ALPHA2,3-SIALYLERING OG ALPHA2,6-SIALYLERING HVOR 80% ELLER MERE AF DEN TOTALE SIALYLERING ER ALPHA2,3-SIALYLERING OG HVOR FRA 5% TIL 20% AF DEN TOTALE SIALYLERING ER ALPHA2,6-SIALYLERING, SAERLIGT FOLLITROPIN DELTA; REG. NO/DATE: EU/1/16/1150/001-003 20161214
SPC/GB01/022 United Kingdom   Start Trial PRODUCT NAME: RECOMBINANT HUMAN LUTEINISING HORMONE; REGISTERED: UK EU/1/00/155/001-006 20001129
122010000006 Germany   Start Trial PRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTRATION NO/DATE: EU/1/09/609/001-002 20100125
1790023-4 Sweden   Start Trial PERIOD OF VALIDITY (FROM - UNTIL): 20290417 - 20311213
PA2017018 Lithuania   Start Trial PRODUCT NAME: REKOMBINANTINIS FSH, ISKAITANT ALFA 2,3-SIALINIMA IR ALFA 2,6-SIALINIMA, KUR 80 PROCENTU ARBA DAUGIAU BENDRO SIALINIMO YRA ALFA 2,3-SIALINIMAS IR KUR NUO 5 IKI 20 PROCENTU BENDRO SIALINIMO YRA ALFA 2,6-SIALINIMAS, YPATINGAI FOLITROPINAS DELTA; REGISTRATION NO/DATE: EU/1/16/1150 20161212
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
AstraZeneca
McKesson
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.